Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma

Ayesha Abdeen1, Alexander J Chou, John H Healey

  • 1Department of Orthopaedic Surgery, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY, USA.

Cancer
|August 12, 2009
PubMed
Abstract

Insights

Vascular Endothelial Growth Factor Receptor 3 (VEGF-R3) expression negatively correlates with osteosarcoma patient survival. VEGF-B indicates a poor response to chemotherapy, highlighting the VEGF pathway's role in osteosarcoma progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Osteogenic sarcoma exhibits variable expression of key cell-signaling proteins like VEGF, IGF, EGF, AKT, PDGF, MAPK, and p70S6 kinase.
  • These protein expressions may hold future significance for osteosarcoma prognostication and targeted therapeutic strategies.
  • The study aimed to investigate the correlation between the expression of these proteins and clinical outcomes in osteosarcoma patients.

Purpose of the Study:

  • To determine the relationship between the expression of specific cell-signaling proteins and clinical outcomes in osteogenic sarcoma.
  • To identify potential prognostic markers within the investigated signaling pathways.
  • To explore the role of these proteins in predicting patient survival and response to chemotherapy.

Main Methods:

  • Utilized a paraffin-embedded tissue microarray of 48 human osteogenic sarcoma specimens.
  • Performed immunohistochemical staining for VEGF, IGF, EGF, AKT, PDGF, MAPK, and p70S6 kinase (total and phosphorylated forms).
  • Correlated protein expression with overall survival (OS), event-free survival (EFS), histologic response to chemotherapy, and serum markers.

Main Results:

  • A negative correlation was observed between VEGF receptor 3 (VEGF-R3) expression and both OS and EFS.
  • VEGF-B expression was associated with a poor histologic response to chemotherapy.
  • Multiple correlations were found between proteins from various signaling pathways (P < .05), while serum markers showed no significant correlation with specific proteins.

Conclusions:

  • The VEGF signaling pathway appears to be critically involved in osteogenic sarcoma.
  • Specific proteins within the VEGF pathway demonstrate prognostic potential.
  • Further investigations are warranted to elucidate the prognostic value of these identified proteins in osteosarcoma.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Growth of Cartilage and Bone Tissue01:27

Growth of Cartilage and Bone Tissue

Chondrocytes form a temporary cartilaginous model by dividing and secreting a thick gel-like extracellular matrix. Once the chondrocytes undergo programmed cell death, osteoblasts enter the site of the cartilaginous model. The process of replacing the temporary cartilaginous model with bone in an ordered manner is called endochondral ossification. In endochondral ossification, not all of the cartilage is replaced by bone tissue. Some cartilage that performs a protective and supportive function...